高级管理人员薪酬管理制度 第一章 总则 第一条 为进一步完善公司高级管理人员的薪酬管理，健全科学有效的 激励和约束机制，充分调动其工作积极性和创造性，提高公司经营效益和管 理水平，确保公司战略目标的实现，根据《中华人民共和国公司法》（以下 简称"《公司法》"）、中国证监会监管规则以及《仙乐健康科技股份有限 公司章程》（以下简称"《公司章程》"）的有关规定，结合本公司实际情 况，特制定本制度。 第二条 本制度适用于公司高级管理人员，包括总经理、副总经理、董 事会秘书、财务负责人及《公司法》和《公司章程》规定的其他高级管理人 员。 第三条高级管理人员薪酬的确定和管理应遵循以下原则： 仙乐健康股份有限公司 （一）薪酬水平与市场价值规律相符，与公司经营效益及工作目标挂 钩； （二）权利义务对等，薪酬与岗位价值高低、承担责任大小相符； （三）激励与约束并重、奖罚对等、绩效优先、兼顾公平； （四）薪酬与公司战略发展相结合，促进公司长期、可持续发展。 第二章 薪酬管理机构 第四条 薪酬与考核委员会是本制度实施的管理机构，在公司董事会授 权下负责确定及调整具体薪酬方案、考核标准、发放安排等事项，对公司高 级管理人员进行考核， ...

Company and Industry Summary Company Overview - The company is a leader in the health and nutrition sector, focusing on the CDMO (Contract Development and Manufacturing Organization) field for nutritional health products. The global health supplement market reached $175 billion in 2023, with an expected growth rate of 6% in 2024 [1][2]. Key Points from the Earnings Call Market Dynamics - The Chinese market is projected to reach $40 billion in 2024, approximately double the size of the U.S. market. The Asia-Pacific market is expected to grow to $39 billion at a rate of around 5% [2]. - The European market is also showing steady growth, with expectations to reach $31 billion in 2024 [2]. Company Performance - For the first three quarters of 2024, the company reported revenue of ¥3.048 billion, a year-on-year increase of 21.8%. Net profit attributable to shareholders was ¥239 million, up 29.52% [6][7]. - In Q3 alone, revenue was ¥1.058 billion, reflecting a 10.43% year-on-year growth, while net profit was ¥85.32 million, a 1.63% increase [6][7]. Strategic Initiatives - The company is focusing on six major investment themes, including global market coverage, multi-category service capabilities, brand influence, R&D innovation, advanced manufacturing systems, and an international management team [4][5][6]. - The company is leveraging its competitive advantages to replicate its success in the Chinese market globally, utilizing consumer insights and market information integration [2][3]. Regional Performance - The Americas division is experiencing rapid growth, with strong demand in both the U.S. and Latin America. The company has successfully integrated its sales teams across regions to enhance cross-selling opportunities [8][9]. - The Asia-Pacific market is also expanding, with new product registrations and customer acquisitions contributing significantly to sales [15][16]. Challenges and Adjustments - The company is facing structural changes in the Chinese market, with a reported industry growth rate of only 1% in the first half of 2024. However, the company remains optimistic about long-term growth prospects [17][18]. - Adjustments in sales strategies and organizational structure are being implemented to better respond to market changes and enhance customer service capabilities [22][23]. Innovation and R&D - The company has emphasized innovation, with over 30% of total sales revenue coming from new products. The gross margin for innovative products exceeds 40% [27][28]. - The establishment of a high-level anti-aging research institute is aimed at supporting sustainable growth and innovation in product development [27]. Operational Efficiency - The company has made significant strides in cost reduction and operational efficiency, achieving over 70% of its annual cost reduction targets by Q3 [29][30]. - The introduction of automated packaging lines in its European facilities is expected to enhance customer satisfaction and reduce delivery times [14][31]. Future Outlook - The company anticipates continued growth in the Asia-Pacific region and is preparing for a robust performance in 2025 and beyond, supported by organizational enhancements and strategic partnerships [16][32]. - The focus on high-value customers and digital marketing strategies is expected to drive future sales growth [25][26]. Conclusion The company is well-positioned in the health and nutrition market, with strong growth prospects driven by strategic initiatives, regional expansion, and a commitment to innovation. Despite facing challenges in the Chinese market, the overall outlook remains positive, supported by operational improvements and a focus on high-value customer segments.

仙乐健康科技股份有限公司 投资者关系活动记录表 证券代码：300791 证券简称：仙乐健康 证券代码：123113 证券简称：仙乐转债 仙乐健康科技股份有限公司 2024 年 10 月 30 日投资者关系活动记录表 编号： 2024-009 | --- | --- | |-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 活动类别 | □ 分析师会议 \n ■ 业绩说明会 \n □ 路演活动 | | 参与单位名称 及人员姓名 | | | 时间 | 30 日 15:30-17:30 | | 方式 | 路演天下 " （ https://rs.p5w.net/ ）采用网络远程的方式召开 | | 上市公司 接待人员姓名 | 董事长、总经理：林培青 董事、副总经理：姚壮民 独立董事：胡世明 副总经理、 ...

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2024-096 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 仙乐健康科技股份有限公司 关于董事、高级管理人员增持公司股份计划进展 暨实施时间过半的公告 公司董事、副总经理姚壮民先生保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要提示： （六）本次增持计划实施方式：由计划增持主体通过深圳证券交易所交易系 统按照相关法律法规许可的方式（包括但不限于集中竞价交易和大宗交易方式） 增持公司股票。 1、仙乐健康科技股份有限公司（以下简称"公司"）于 2024 年 7 月 25 日 披露了《关于董事、高级管理人员增持公司股份计划的公告》（公告编号：2024- 74）（以下简称"增持计划公告"），公司董事、副总经理姚壮民先生（下称 "姚 壮民先生"或"计划增持主体"）计划自本次增持计划公告之日起 6 个月内（即 2024 年 7 月 26 日至 2025 年 1 ...

Investment Rating - Buy (maintained) [2] Core Views - The company's domestic business is under pressure, while overseas markets continue to show strong growth [1] - The company is expected to achieve its revenue target for 2024, but the net profit target may face challenges due to domestic business pressures [2] - Overseas regions, particularly the Americas and Asia-Pacific, are expected to outperform domestic markets, with the Americas benefiting from the acquisition of BF and cross-synergy sales [3] - The company's gross margin saw a slight year-on-year fluctuation, with minority shareholder losses narrowing quarter-on-quarter but still impacting profitability [3] - The company is a leading CDMO player in the health supplement industry, with a global supply chain and strong R&D capabilities [5] Financial Performance - In Q3 2024, the company achieved revenue of RMB 10.58 billion, a year-on-year increase of 10.43%, with net profit attributable to shareholders of RMB 0.85 billion, up 1.63% year-on-year [3] - For the first three quarters of 2024, the company achieved revenue of RMB 30.48 billion, a year-on-year increase of 21.8%, and net profit attributable to shareholders of RMB 2.40 billion [3] - The company's gross margin in Q3 2024 was 29.63%, a year-on-year decrease of 1.65 percentage points [3] - The company's net profit margin attributable to shareholders in Q3 2024 was 8.07%, a year-on-year decrease of 0.69 percentage points [3] Market Data - The current stock price is RMB 26.60, with a 52-week price range of RMB 21.22-43.38 [2] - The company's total market capitalization is RMB 6,274.22 million, with a circulating market capitalization of RMB 5,170.45 million [2] - The company's total shares outstanding are 235.87 million, with 194.38 million shares in circulation [2] - The average daily trading volume is RMB 170.23 million, with a monthly turnover rate of 2.17% [2] Growth and Profitability Forecast - Revenue is expected to grow to RMB 43.13 billion in 2024, RMB 49.27 billion in 2025, and RMB 56.17 billion in 2026, with year-on-year growth rates of 20%, 14%, and 14% respectively [5][6] - Net profit attributable to shareholders is expected to reach RMB 3.60 billion in 2024, RMB 4.50 billion in 2025, and RMB 5.60 billion in 2026, with year-on-year growth rates of 28%, 25%, and 25% respectively [5][6] - EPS is forecasted to be RMB 1.53 in 2024, RMB 1.91 in 2025, and RMB 2.37 in 2026 [5][6] - ROE is expected to increase from 14% in 2024 to 18% in 2026 [6] Valuation Metrics - The company's P/E ratio is expected to be 17.41x in 2024, 13.95x in 2025, and 11.20x in 2026 [5][6] - The P/B ratio is forecasted to be 2.44x in 2024, 2.24x in 2025, and 2.04x in 2026 [6] - The P/S ratio is expected to decrease from 1.45x in 2024 to 1.12x in 2026 [6] Operational and Financial Metrics - The company's total asset turnover ratio is expected to improve from 0.77 in 2024 to 0.83 in 2026 [8] - The debt-to-asset ratio is forecasted to remain stable at around 55% from 2024 to 2026 [8] - Operating cash flow is expected to increase from RMB 5.59 billion in 2024 to RMB 8.44 billion in 2026 [8]

1 （问题征集专题页面二维码，扫码自动匹配移动端） 欢迎广大投资者积极参与。 | 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2024-095 | | --- | --- | --- | | 证券代码：123113 | 证券简称：仙乐转债 | | 仙乐健康科技股份有限公司 关于举行 2024 年第三季度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司（以下简称"公司"）已于 2024 年 10 月 24 日 披露了 2024 年第三季度报告。为便于广大投资者更深入全面地了解公司情况， 公司定于 2024 年 10 月 30 日（星期三）下午 15:30 至 17:30 在全景网举办 2024 年第三季度业绩说明会，本次业绩说明会将采用网络远程的方式举行，投资者可 登陆"全景•路演天下"（http://rs.p5w.net）参与本次业绩说明会。 出席本次 2024 年第三季度业绩说明会的人员有：公司董事长兼总经理林培 青先生、董事兼副总经理姚壮民先生、副总经理兼董事会秘书郑丽群女士、财务 负责人夏凡 ...

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 监事会会议召开情况 仙乐健康科技股份有限公司（以下简称"公司"）于 2024 年 10 月 22 日以通 讯会议方式召开第四届监事会第三次会议。会议召开通知于 2024 年 10 月 18 日 以电子邮件、微信信息等方式送达给全体监事。本次会议由监事会主席谢盈瑜召 集和主持，应出席监事 3 人，实际出席监事 3 人。本次会议的召集、召开符合 《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》《仙乐健康科技股份有限公 司章程》和《仙乐健康科技股份有限公司监事会议事规则》的有关规定，会议合 法有效。 | 证券代码：300791 | 证券简称：仙乐健康 公告编码：2024-091 | | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | 仙乐健康科技股份有限公司 第四届监事会第三次会议决议公告 二、监事会会议审议情况 经与会监事认真审议，本次会议以回收表决票的表决方式表决通过了以下决 议： 1、审议通过了《20 ...

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2024-090 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 仙乐健康科技股份有限公司 第四届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 仙乐健康科技股份有限公司（以下简称"公司"）第四届董事会第三次会议 于 2024 年 10 月 22 日以通讯会议方式召开。会议通知于 2024 年 10 月 18 日以 电子邮件、微信信息等方式送达给全体董事及其他列席人员。本次会议由董事长 林培青先生召集和主持，应出席董事 7 人，实际出席董事 7 人。公司监事、高级 管理人员列席本次会议。本次会议的召集、召开符合《中华人民共和国公司法》 《中华人民共和国证券法》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》《仙乐健康科技股份有限公司章程》和《仙乐健康科 技股份有限公司董事会议事规则》的有关规定，会议合法有效。 1、审议通过了《2024 年第三季度报告》 经审议， ...

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2024-094 | | --- | --- | --- | | 证券代码：123113 | 证券简称：仙乐转债 | | 欢迎广大投资者积极参与。 仙乐健康科技股份有限公司 出席本次 2024 年第三季度业绩说明会的人员有：公司董事长兼总经理林培 青先生、董事兼副总经理姚壮民先生、副总经理兼董事会秘书郑丽群女士、财务 负责人夏凡女士、投资者关系总监刘若阳先生、独立董事胡世明先生、保荐代表 人刘兴德先生。 仙乐健康科技股份有限公司 为充分尊重投资者、提升交流的针对性，现就公司 2024 年第三季度业绩说 明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2024 年 10 月 30 日（星期三）下午 15:30 前访问 http://ir.p5w.net/zj/，或扫描下方 二维码，进入问题征集专题页面。公司将通过本次业绩说明会，在信息披露允许 范围内就投资者普遍关注的问题进行回答。 关于举行 2024 年第三季度网上业绩说明会的公告 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重 ...

Investment Rating - Buy rating maintained for the company [1] Core Views - The company is a global leader in the nutrition and health food CDMO sector, with a strong focus on both R&D and manufacturing, and a global presence in both domestic and overseas markets [1] - The company has shown strong performance relative to the CSI 300 index, with a 54.8% increase over the past 12 months [1] - The global health supplement market is highly resilient, with a CAGR of 6.5% from 2020 to 2023, and China's market growing at a higher rate of 7.0% during the same period [2] - The company's revenue has grown from RMB 1.58 billion in 2019 to RMB 3.58 billion in 2023, with a CAGR of 22.72%, and net profit has grown from RMB 143 million to RMB 281 million, with a CAGR of 18.50% [3] - The company's overseas revenue has been increasing, with 2023 revenue distribution at 51.67% in China, 14.77% in Europe, 29.15% in the Americas, and 4.41% in other regions [3] Company Overview - The company was founded in 1993 as a pharmaceutical company and transitioned to the nutrition and health food CDMO sector in 2000 [3] - It has expanded globally through strategic acquisitions, including Ayanda in Germany in 2016 and Best Formulations in North America in 2023 [3] - The company has a diversified product portfolio, including soft capsules, gummies, tablets, powders, hard capsules, and nutritional beverages, catering to various consumer needs [22][23] - The company has a strong R&D capability with five global R&D centers and a team led by PhDs, enabling it to provide innovative product solutions [4] - The company has a global supply chain with seven production bases, leveraging China's engineering advantages to enhance R&D efficiency and reduce procurement costs [4] Industry Analysis - The global health supplement market is expected to grow steadily, driven by increasing consumer health awareness and product innovation [2] - The health supplement industry exhibits counter-cyclical characteristics, with demand often remaining strong during economic downturns [2] - The Chinese market, as the second-largest globally, has significant growth potential, with per capita consumption of health supplements at $26 in 2023, much lower than in mature markets like the US and Japan [42][43] - The industry is highly fragmented, with the top 10 brands in China and the US accounting for only 24.6% and 27.5% of the market, respectively, in 2023 [53] - The CDMO model is becoming more prevalent as it offers efficiency advantages for emerging brands, especially in the context of increasing online sales channels [57][59] Future Outlook - The company is expected to continue its growth trajectory, with projected revenues of RMB 4.31 billion, RMB 4.93 billion, and RMB 5.62 billion for 2024, 2025, and 2026, respectively, representing year-on-year growth of 20%, 14%, and 14% [5] - The company's net profit is expected to grow to RMB 387 million, RMB 490 million, and RMB 590 million in 2024, 2025, and 2026, respectively, with corresponding EPS of RMB 1.64, RMB 2.08, and RMB 2.50 [5] - The company's integration of Best Formulations is expected to enhance its market position in North America, with potential for profitability improvements and cost synergies [5] - The company's focus on R&D and manufacturing efficiency, along with its strong customer base, positions it well to capture a larger share of the growing global health supplement market [4][5]